Location History:
- Nanjing, CN (2022)
- Jiangsu, CN (2024)
Company Filing History:
2 out of 13 
1 out of 15 Years Active: 2022-2025
Title: Innovations of Zhongdao Li in Tumor Immunotherapy
Introduction
Zhongdao Li is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of tumor immunotherapy, holding a total of 3 patents. His work focuses on developing bispecific antibodies and fusion proteins that enhance the efficacy of cancer treatments.
Latest Patents
Zhongdao Li's latest patents include the development of an anti-CD47/anti-PD-1 bispecific antibody. This invention relates to a bispecific antibody that can block two mechanisms of tumor immune escape simultaneously, thereby improving the effectiveness of tumor immunotherapy. The antibody consists of a first antigen binding portion that specifically binds to CD47 and a second portion that binds to PD-1.
Another notable patent is for a fusion protein dimer that utilizes an antibody Fc region as a backbone. This fusion protein comprises two polypeptide chains, each containing an antibody Fc region and single-domain antibodies. This innovation not only enhances the activity of single-domain antibodies but also improves the biological activity of cytokines, leading to better anti-tumor potential.
Career Highlights
Zhongdao Li has worked with notable companies such as Nanjing Genscript Biotech Co., Ltd. and Nanjing Legend Biotech Co., Ltd. His experience in these organizations has contributed to his expertise in the field of biotechnology and immunotherapy.
Collaborations
Zhongdao Li has collaborated with esteemed colleagues, including Zhenyu Liu and Chuan-Chu Chou. These partnerships have facilitated the advancement of his research and innovations in tumor immunotherapy.
Conclusion
Zhongdao Li's contributions to the field of tumor immunotherapy through his innovative patents and collaborations highlight his significant role as an inventor. His work continues to pave the way for advancements in cancer treatment.